A 2023 analysis examined a cohort of older adults with heart failure (HFrEF or HFpEF) from Medicare data to compare the adjusted hazard ratios among those taking SGLT2i vs. GLP-1 agonists vs. DPP4i. This evidence concerns the gene GCG and heart failure.